Biomarkers for Parkinson's Disease: Recent Advancement

Overview

Journal Neurosci Bull

Specialty Neurology

Date 2017 Sep 23

PMID 28936761

Citations 99

Authors

Sharvari Lotankar

Kedar S Prabhavalkar

Lokesh K Bhatt

Affiliations

Soon will be listed here.

Abstract

As a multi-factorial degenerative disease, Parkinson's disease (PD) leads to tremor, gait rigidity, and hypokinesia, thus hampering normal living. As this disease is usually detected in the later stages when neurons have degenerated completely, cure is on hold, ultimately leading to death due to the lack of early diagnostic techniques. Thus, biomarkers are required to detect the disease in the early stages when prevention is possible. Various biomarkers providing early diagnosis of the disease include those of imaging, cerebrospinal fluid, oxidative stress, neuroprotection, and inflammation. Also, biomarkers, alone or in combination, are used in the diagnosis and evolution of PD. This review encompasses various biomarkers available for PD and discusses recent advances in their development.

Citing Articles

Vinpocetine and Lactobacillus Attenuated Rotenone-Induced Parkinson's Disease and Restored Dopamine Synthesis in Rats through Modulation of Oxidative Stress, Neuroinflammation, and Lewy Bodies Inclusion.

Hassan H, Abou-Hany H, Shata A, Hellal D, El-Baz A, ElSaid Z J Neuroimmune Pharmacol. 2025; 20(1):22.

PMID: 39954133 DOI: 10.1007/s11481-025-10176-8.

Utilization of nanotechnology to surmount the blood-brain barrier in disorders of the central nervous system.

Luo Q, Yang J, Yang M, Wang Y, Liu Y, Liu J Mater Today Bio. 2025; 31:101457.

PMID: 39896289 PMC: 11786670. DOI: 10.1016/j.mtbio.2025.101457.

Sigma 1 Receptor and Its Pivotal Role in Neurological Disorders.

Shokr M, Badawi G, Elshazly S, Zaki H, Mohamed A ACS Pharmacol Transl Sci. 2025; 8(1):47-65.

PMID: 39816800 PMC: 11729429. DOI: 10.1021/acsptsci.4c00564.

Multi-omics analysis reveals the genetic aging landscape of Parkinson's disease.

Wang Z, Zhang Z, Li P, Cao Q, Fan P, Xia H Sci Rep. 2024; 14(1):31167.

PMID: 39730760 PMC: 11680984. DOI: 10.1038/s41598-024-82470-z.

The cellular and extracellular proteomic signature of human dopaminergic neurons carrying the LRRK2 G2019S mutation.

Knab F, Guaitoli G, Jarboui M, von Zweydorf F, Isik F, Klose F Front Neurosci. 2024; 18:1502246.

PMID: 39726830 PMC: 11669673. DOI: 10.3389/fnins.2024.1502246.

References

Solari N, Bonito-Oliva A, Fisone G, Brambilla R . Understanding cognitive deficits in Parkinson's disease: lessons from preclinical animal models. Learn Mem. 2013; 20(10):592-600. DOI: 10.1101/lm.032029.113. View

Huang L, Grady S, Quik M . Nicotine reduces L-DOPA-induced dyskinesias by acting at beta2* nicotinic receptors. J Pharmacol Exp Ther. 2011; 338(3):932-41. PMC: 3164339. DOI: 10.1124/jpet.111.182949. View

Michell A, Xu Z, Fritz D, Lewis S, Foltynie T, Williams-Gray C . Saccadic latency distributions in Parkinson's disease and the effects of L-dopa. Exp Brain Res. 2006; 174(1):7-18. PMC: 1877863. DOI: 10.1007/s00221-006-0412-z. View

Braak H, Braak E, Yilmazer D, de Vos R, Jansen E, Bohl J . Amygdala pathology in Parkinson's disease. Acta Neuropathol. 1994; 88(6):493-500. DOI: 10.1007/BF00296485. View

Berg D, Steinberger J, Olanow C, Naidich T, Yousry T . Milestones in magnetic resonance imaging and transcranial sonography of movement disorders. Mov Disord. 2011; 26(6):979-92. DOI: 10.1002/mds.23766. View

Varanese S, Birnbaum Z, Rossi R, Di Rocco A . Treatment of advanced Parkinson's disease. Parkinsons Dis. 2011; 2010:480260. PMC: 3038575. DOI: 10.4061/2010/480260. View

Gupta R, Kim C, Agarwal N, Lieber B, Monaco 3rd E . Understanding the Influence of Parkinson Disease on Adolf Hitler's Decision-Making during World War II. World Neurosurg. 2015; 84(5):1447-52. DOI: 10.1016/j.wneu.2015.06.014. View

Brown L, Schneider J, Lidsky T . Sensory and cognitive functions of the basal ganglia. Curr Opin Neurobiol. 1997; 7(2):157-63. DOI: 10.1016/s0959-4388(97)80003-7. View

Bertrand E, Lechowicz W, Szpak G, Dymecki J . Qualitative and quantitative analysis of locus coeruleus neurons in Parkinson's disease. Folia Neuropathol. 1997; 35(2):80-6. View

10.

Vagberg M, Norgren N, Dring A, Lindqvist T, Birgander R, Zetterberg H . Levels and Age Dependency of Neurofilament Light and Glial Fibrillary Acidic Protein in Healthy Individuals and Their Relation to the Brain Parenchymal Fraction. PLoS One. 2015; 10(8):e0135886. PMC: 4552591. DOI: 10.1371/journal.pone.0135886. View

11.

Cerasa A, Messina D, Pugliese P, Morelli M, Lanza P, Salsone M . Increased prefrontal volume in PD with levodopa-induced dyskinesias: a voxel-based morphometry study. Mov Disord. 2011; 26(5):807-12. DOI: 10.1002/mds.23660. View

12.

Frisardi V, Santamato A, Cheeran B . Parkinson's Disease: New Insights into Pathophysiology and Rehabilitative Approaches. Parkinsons Dis. 2016; 2016:3121727. PMC: 4944068. DOI: 10.1155/2016/3121727. View

13.

Teive H, Bertucci Filho D, Munhoz R . Unusual motor and non-motor symptoms and signs in the early stage of Parkinson's disease. Arq Neuropsiquiatr. 2016; 74(10):781-784. DOI: 10.1590/0004-282X20160126. View

14.

Ariga H, Takahashi-Niki K, Kato I, Maita H, Niki T, Iguchi-Ariga S . Neuroprotective function of DJ-1 in Parkinson's disease. Oxid Med Cell Longev. 2013; 2013:683920. PMC: 3671546. DOI: 10.1155/2013/683920. View

15.

Nakamura K, Sugaya K . Neuromelanin-sensitive magnetic resonance imaging: a promising technique for depicting tissue characteristics containing neuromelanin. Neural Regen Res. 2014; 9(7):759-60. PMC: 4146273. DOI: 10.4103/1673-5374.131583. View

16.

Giompres P, Delis F . Dopamine transporters in the cerebellum of mutant mice. Cerebellum. 2005; 4(2):105-11. DOI: 10.1080/14734220510007851. View

17.

Delenclos M, Jones D, McLean P, Uitti R . Biomarkers in Parkinson's disease: Advances and strategies. Parkinsonism Relat Disord. 2015; 22 Suppl 1:S106-10. PMC: 5120398. DOI: 10.1016/j.parkreldis.2015.09.048. View

18.

Seifert K, Wiener J . The impact of DaTscan on the diagnosis and management of movement disorders: A retrospective study. Am J Neurodegener Dis. 2013; 2(1):29-34. PMC: 3601468. View

19.

Costa A, Peppe A, Carlesimo G, Zabberoni S, Scalici F, Caltagirone C . Brain-derived neurotrophic factor serum levels correlate with cognitive performance in Parkinson's disease patients with mild cognitive impairment. Front Behav Neurosci. 2015; 9:253. PMC: 4569860. DOI: 10.3389/fnbeh.2015.00253. View

20.

Niccolini F, Politis M . A systematic review of lessons learned from PET molecular imaging research in atypical parkinsonism. Eur J Nucl Med Mol Imaging. 2016; 43(12):2244-2254. PMC: 5047923. DOI: 10.1007/s00259-016-3464-8. View